lifestyle.thriveinsider.com

Author: Anixa Biosciences, Inc.

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

February 11, 2026
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

February 2, 2026
Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

January 27, 2026
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

December 15, 2025
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

December 12, 2025
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

December 10, 2025
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

November 19, 2025
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

November 14, 2025
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

November 8, 2025